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Background: In Alzheimer disease (AD), hyperphosphorylation of tau proteins results in microtubule destabilization
and cytoskeletal abnormalities. Our prior ultra-morphometric studies documented a clear reduction in microtubules
in pyramidal neurons in AD compared to controls, however, this reduction did not coincide with the presence of
paired helical filaments. The latter suggests the presence of compensatory mechanism(s) that stabilize microtubule
dynamics despite the loss of tau binding and stabilization. Microtubules are composed of tubulin dimers which are
subject to posttranslational modifications that affect the stability and function of microtubules.
Methods: In this study, we performed a detailed analysis on changes in the posttranslational modifications in tubulin in
postmortem human brain tissues from AD patients and age-matched controls by immunoblot and immunocytochemistry.
Results: Consistent with our previous study, we found decreased levels of α-tubulin in AD brain. Levels of tubulin
with various posttranslational modifications such as polyglutamylation, tyrosination, and detyrosination were also
proportionally reduced in AD brain, but, interestingly, there was an increase in the proportion of the acetylated
α-tubulin in the remaining α-tubulin. Tubulin distribution was changed from predominantly in the processes to
be more accumulated in the cell body. The number of processes containing polyglutamylated tubulin was well
preserved in AD neurons. While there was a cell autonomous detrimental effect of NFTs on tubulin, this is
likely a gradual and slow process, and there was no selective loss of acetylated or polyglutamylated tubulin in
NFT-bearing neurons.
Conclusions: Overall, we suggest that the specific changes in tubulin modification in AD brain likely represent
a compensatory response.
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Alzheimer disease (AD), as the most common neurodegen-
erative disease, is characterized by the pathological markers
such as intracellular neurofibrillary tangles (NFTs) and
extracellular senile plaques. NFTs are mainly composed of
a highly phosphorylated form of the microtubule associated
protein tau, and senile plaques are primarily composed of
amyloid-β. Physiologically, tau regulates microtubule stabil-
ity by binding to microtubules. Phosphorylation and de-
phosphorylation of tau at specific sites such as Ser262 or* Correspondence: xiongwei.zhu@case.edu
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unless otherwise stated.Thr231 regulates its binding ability to microtubules [1, 2].
In AD patients, hyperphosphorylated tau proteins have low
tubulin-binding activity and form paired helical filaments
which are believed to lead to microtubule destabilization
and cytoskeletal abnormalities [3].
Our previous ultra-morphometric study demonstrated
that microtubules are significantly reduced in number and
length in AD neurons, however, their loss does not corres-
pond with the formation of paired helical filaments [4]. In
fact, abundant microtubules were often seen in close
juxtaposition to paired helical filaments, suggesting that
microtubule deficit is independent of tau filament forma-
tion [4]. Even though the overall function of microtubules
and cellular actions dependent on microtubules including
axonal transport are likely compromised [5–8], neuronsThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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increased levels of phosphorylated tau proteins and depos-
ited filaments [9, 10]. This suggests the presence of
mechanism(s) compensating for the loss of tau binding/
stabilizing activity affecting microtubules in these neurons.
Microtubules are composed of tubulin heterodimers made
of α- and β-tubulin. The C-terminal tail of α-tubulin is
subject to posttranslational modifications such as detyrosi-
nation, acetylation, and polyglutamylation, which affects
the function and stability of microtubules [11, 12]. We
hypothesize that compensatory changes in posttranslational
modification of tubulin could alleviate deficits induced by
microtubule destabilization/reduction in susceptible neurons
in AD brain. To begin to test this hypothesis, we performed
a detailed immunoblot and immunocytochemical analysis to
investigate various posttranslational modifications to tubulin
in the brain tissue from AD and control patients.
Methods
Human tissues and Immunocytochemistry
Human brain tissue samples were obtained postmortem
from patients with histopathologically-confirmed AD
(n = 3) (see Table 1) and non-AD controls (n = 4. Except
for the lack of NFTs, the young control case (C1) dem-
onstrated similar staining pattern as other controls cases
for all the antibodies used). Tissue was fixed in metha-
carn (methanol:chloroform:acetic acid in a 6:3:1 ratio)
immersion for 24 h at 4 °C. Tissue was subsequently
dehydrated through graded ethanol and xylene solutions,
embedded in paraffin, and sectioned at 6 μm. Following hy-
dration, sequential sections were immunostained by the
peroxidase-antiperoxidase procedure with DAB as chromo-
gen [13] using mouse monoclonal antibodies against α-
tubulin (Epitomics, Burlingame, CA, USA), acetylated tubu-
lin (Sigma, St. Louis, MO, USA, product#T6793), tyrosi-
nated tubulin (Sigma, Product# T9028), detyrosinated
tubulin (Chemicon, cata#MAB5566) and polyglutamylated
tubulin (Sigma, Product#T9822). Sections were also double
stained for NFT using a rabbit antibody against tau protein
and the alkaline phosphatase anti alkaline phosphatase
method and developed with Fast Blue.Table 1 Details of Alzheimer disease and control cases used in
the immunocytochemical studies
Case Neuropathological Diagnosis Gender Age # NFT/mm2 CA1
AD 1 Alzheimer disease F 76 55.4
AD 2 Alzheimer disease, severe F 77 81.6
AD 3 Alzheimer disease F 88 29.9
C 1 No pathological diagnosis M 62 0
C 2 Infarcts F 69 0.8
C 3 No pathological diagnosis F 74 8.1
C 4 No pathological diagnosis M 81 7.8Double-label immunofluorescence images
Following rehydration brain tissue sections were blocked
with 10 % normal goat serum in phosphate-buffered saline
for 1 h, then incubated with primary antibody pSer396
(Biosource, Camarillo, CA, USA. 1:200) and acetylated
tubulin overnight at 4 °C. Following three washes, the sec-
tions were incubated with 488/564-conjugated secondary
antibody (Invitrogen, Grand Island, NY, USA) (1:500) for
1 h at 37 °C in the dark. Tissues were rinsed three times
with phosphate-buffered saline and mounted with antifade
medium (Southern Biotech, Birmingham, AL, USA). All
fluorescence images were captured with a Zeiss LSM 510
inverted fluorescence microscope or a Zeiss LSM 510
inverted laser-scanning confocal fluorescence microscope.
Western blotting
Samples of frozen gray matter of hippocampus of AD
(n = 9, age 78.3 ± 1.7, postmortem interval of 6 ± 1.6 h)
and control cases (n = 8, ages 74.1 ± 4.7, postmortem
interval of 7.4 ± 2 h, there was no significant difference
in the age and postmortem intervals between AD and
control groups) were homogenized in 10 x volumes of
lysis buffer (Cell Signaling, Danvers, MA, USA) and cen-
trifuged for 10 min at 16,000 x g. Protein concentration
of the supernatants was determined by the bicinchoninic
acid assay method (Pierce, Rockford, IL, USA). Western
blot was performed to examine α-tubulin, acetylated tubu-
lin, tyrosine tubulin, polyglutamylated tubulin, detyrosinated
tubulin, and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) (Millipore, Bedford, MA, USA) levels in samples.
Blots were scanned at high resolution and the immuno-
reactive bands were quantitated with Quantity One soft-
ware (Bio-rad, Hercules, CA, USA). The quantification
results (means ± SEM) were analyzed used the Student's
t-test to determine the significance (p < 0.05).
Results
Levels of post-translational modifications of tubulin in the
hippocampus, including acetylated tubulin, tyrosinated
tubulin, detyrosinated tubulin, and polyglutamylated tubu-
lin along with total expression levels of α-tubulin, were
determined by western blot (Fig. 1a). Expression levels of
GAPDH were also determined by western blot as an in-
ternal loading control. Quantitative analysis, normalized
to the levels of GAPDH (Fig. 1b), revealed that levels of
total α-tubulin were significantly reduced by approxi-
mately 65 % in the brains from AD patients compared to
age-matched control brains. Similarly, levels of acetylated
tubulin, polyglutamylated tubulin, tyrosinated tubulin, and
detyrosinated tubulin were also significantly reduced in
AD brain (Fig. 1b). The significant reduction of tyrosi-
nated tubulin, detryosinated tubulin, and polygluatmylated
tubulin in the AD brains was proportional to the reduc-
tion of the total α-tubulin since there was no difference
Fig. 1 Immunoblot analysis of tubulins in AD brain. (a) Representative immunoblot analysis of tubulin expression and post-translational modifications
in brain homogenates from hippocampal tissues from AD and age-matched control patients. GAPDH was used as the internal loading control. (b) The
quantification results, normalized to GAPDH levels, confirmed a significant decrease in α-tubulin, acetylated tubulin, polyGlu-tubulin, tyrosinated tubulin,
and detyr-tubulin levels. (c) The quantification results, normalized to α-tubulin levels, demonstrated an increase in acetylated tubulin (Ace TUB). Data
are means ± SEM. * indicates significant difference between AD and control with p < 0.05
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modified tubulins were normalized to total α-tubulin
(Fig. 1c). However, when normalized to total α-tubulin,
the ratio of acetylated tubulin was significantly increased
by approximately 31 % in AD compared to controls
(Fig. 1c), suggesting that acetylated tubulin is more resist-
ant to degradation in AD.
We next examined the localization of the various
tubulin populations in AD and control hippocampal sec-
tions by immunocytochemistry. At the light level, all
cases examined showed clear and specific immunostain-
ing for each of the monoclonal tubulin modificationantibodies. The same region of the CA1 was shown for
each antibody in a control case with no NFT and in an
AD case with blue-stained NFT (Fig. 2a). All the tubulin
antibodies stained many long axonal processes plus finer
processes between axons and occasional neuronal cell
bodies in the control cases. The AD cases appeared to
have fewer axons stained but the cell bodies were more
apparent. Further, qualitatively, there appeared to be
fewer of the finer processes immunostained in the AD
cases, such that only the thicker processes were stained.
Quantification of the immunostained axonal processes
in the CA1 region by each of these tubulin antibodies
Fig. 2 Immunocytochemical analysis of tubulins in AD brain. Representative images of the CA1 region demonstrate specific staining of the
tubulin antibodies for neuron cell bodies and axonal processes in both control and AD cases (a). Tubulin antibodies are stained brown and NFT,
using tau antibody, are stained blue. Qualitatively it appears that there are fewer processes stained in the AD cases and that only the thicker
processes are retained (A). Quantification found there are significantly fewer processes stained for alpha, acetylated, tyrosinated, and
detyrosinated tubulin in AD cases (b). When normalized to α-tubulin levels, an increase in stable glutamylated tubulin was found in AD
cases (c). *p < 0.05. Scale bar = 50 μm
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ber of processes stained was significantly lower in the
CA1 for the α-tubulin, and the acetylated, tyrosinated,
and detyrosinated modifications while there was only a
trend of reduction for the polyglutamylated tubulin that
did not reach significance (Fig. 2b). Within each case, it
was possible to directly compare how each modification
was maintained in the CA1 neuronal population relative
to α-tubulin. No significant difference was found in the
proportion of processes with acetylated, tyrosinated, ordetyrosinated tubulin between AD and control, but the
proportion of processes with polyglutamylated tubulin
was significantly increased in AD (Fig. 2c).
To discern the potential effects of NFTs on tubulin ex-
pression and modifications, double staining methods
were employed. For each modification, other than the
few ghost NFTs, all the NFT-bearing neurons contained
various levels of tubulins, either in the axons or also in
the cell body. Among all cases examined, the majority of
NFT-bearing neurons counted in the entire CA1 region
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process stained for tubulin, yet maintained some tubulin
immunoreactivity in the cell body (arrowheads in Fig. 3a,
left panels), however, for each modification, there were
still some NFT-bearing neurons (on average around
22 %) with long axonal processes stained for tubulins
(Fig. 3a, right panels, arrows). The pathological tau
(stained blue) was restricted to the cell body and only aFig. 3 The relationship between neuronal tubulin levels and NFTs. Most ne
stained for tubulins (a, arrowheads left panels). However, some neurons wi
(A, arrows). Every tubulin modification was retained in the axonal process i
Measuring the lengths of the cell bodies and axonal processes in the NFT and
indeed significantly shorter (b) in all AD cases and one control case. Taken tog
when compared to the normal neuron population (c), yet no difference in len
normal neurons, suggesting the loss of axonal process length is a result of NFshort distance down the axon. Measuring the length of
the cell body and stained axonal processes revealed sig-
nificantly shorter neurons/processes when NFT were
present, compared to all surrounding tubulin-positive
cells lacking NFT in all AD cases and the control cases
with NFT (Fig. 3b,c). Yet, no difference was noted in
these normal neurons or NFT-bearing neurons between
the AD and control cases (Fig. 3c), suggesting the neuronalurons with NFT (mean 78 %) did not demonstrate axonal processes
th NFT (blue), had tubulin staining in the cell body and axonal process
n some NFT-bearing neurons (A, right panels). Scale bars = 50 μm.
normal surrounding neurons in the CA1 region found the NFTs were
ether, the NFT in both AD and control cases, were significantly shorter
gth was found when comparing AD and control NFT, or AD and control
T formation and not disease. *p < 0.001, **p < 0.05
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ology and not disease state.
It was previously reported that NFT-bearing neurons
contain less acetylated tubulin [14]. However, such a pat-
tern was not confirmed in our study as various levels of
acetylated tubulin were observed in NFT-bearing neurons
similar to that of the NFT-free neurons. NFT-bearing neu-
rons with comparable levels of acetylated tubulin as com-
pared to those neighboring neurons without NFTs were
frequently observed. This staining pattern was noted in
using light level immunohistochemistry and was also con-
firmed with double label fluorescent microscopy (Fig. 4).
Similarly, various levels of polyglutamylated tubulin were
also observed in NFT-bearing neurons with many NFT-
bearing neurons demonstrating comparable levels of poly-
glutamylated tubulin as compared to neighboring neurons
without NFT, again seen using both staining methodolo-
gies (Fig. 5).
Discussion
One of the key features associated with AD is hyperpho-
sphorylation of tau protein which reduces its binding af-
finity to microtubules, thus resulting in instability and
dysfunction of microtubule and related axonal transport
[3]. However, despite the fact that tangle bearing neu-
rons lose substantial amounts of structurally normal
microtubules [6, 15], prior studies demonstrated that
neurons survive decades in the presence of tangles [16].
This suggests that possible compensatory mechanisms
may support a sufficiently efficient microtubule network
and axonal transport and/or a gradual loss of essential
functions of microtubule network. In the current study,
we made several interesting observations: 1) there were
significantly reduced levels of α-tubulin along with pro-
portional reduction in the absolute levels of polygluta-
mylated, tyrosinated, and detyrosinated tubulin in the
AD brain; 2) despite the significant reduction in the
absolute level, acetylated tubulin was proportionally in-
creased in the remaining α-tubulin in the AD brain; 3)Fig. 4 NFT-bearing neurons do not necessarily contain less acetylated tubu
tissues, those neurons containing neurofibrillary pathology (red, arrowhead
without NFT (arrows). (b) The same pattern was found using light level mic
stained blueα-tubulin and modified tubulins were more accumulated
in the cell bodies and thicker processes in AD neurons
compared to predominant distribution in both thicker
axonal processes and finer branches in neurons in the
control brain; 4) the number of processes decorated by
polyglutamylated tubulin was not significantly decreased
in AD brain. In fact, it was proportionally and signifi-
cantly increased in AD when normalized with that of α-
tubulin; 5) the majority of NFT-bearing neurons lack
tubulin-decorated axons, but there were still significant
number of NFT-bearing neurons with such long axons;
and 6) there was no correlation between the presence of
NFTs and the immunoreactivity of acetylated tubulin or
polyglutamylated tubulin in the neurons in AD brain.
The finding of decreased total expression levels of
α-tubulin and the decreased number of α-tubulin posi-
tive axonal processes in the AD cases in the present
work is consistent with our previous ultrastructural ana-
lysis study, which shows that both number and total
length of microtubules were significantly and selectively
reduced in pyramidal neurons from AD in comparison
to control cases [4]. Indeed, other deficiencies related to
abnormal microtubules such as deficits in fast axonal
transport, dystrophic neurites, and abnormal mitochon-
drial distribution [6, 17–20] are also reported in AD
brains, suggesting that decreased α-tubulin expression
could contribute to such deficits and to the pathogenesis
of AD. It is not clear what the functional significance of
increased levels of α-tubulin in the cell body and the
proximal end of the axon processes, but it explains the
observation of close juxtaposition of abundant microtu-
bules to paired helical filaments [4] since NFTs are nor-
mally accumulated in these regions.
One interesting finding in our study is that despite the
reduction in the absolute levels of acetylated tubulin in
AD brain, when normalized to reduced levels of α-
tubulin, there is increased proportion of acetylated tubu-
lin in the remaining α-tubulin in AD. Acetylation occurs
after microtubule assembly at the ε-amine of lysine 40lin. (a) Confocal microscopy demonstrated that in AD hippocampal
s) display levels of acetylated tubulin (green) comparable to those
roscopy with acetylated tubulin stained brown, and phospho-tau
Fig. 5 NFT-bearing neurons do not necessarily contain less polyglutamylated tubulin. (a) Levels of polyglutamylated tubulin (red) are similar in both
normal and NFT-bearing neurons stained with phosphorylated tau (green). Blue: DAPI. (b) The same pattern was found using light level microscopy
with glutamylated tubulin stained brown, and phospho-tau stained blue
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which is preserved in α-tubulin but not β-tubulin [21,
22]. Acetylated α-tubulin is present in stable, long-lived
microtubules with slow dynamics [23]. One interpret-
ation is that microtubules containing acetylated α-tubulin
are better preserved than other microtubules in AD
brains. This may be due to its distinct localization in ma-
ture neurons as it is enriched in the proximal site of the
axon and dendrites [24]. Indeed, our results indicated that
the thicker axonal processes are better preserved while
those finer processes likely representing branches are lost
in AD neurons.
The function of tubulin acetylation remains to be fully
understood. Although the early studies indicated that
acetylation itself does not confer stability unto microtu-
bules, it was difficult to distinguish whether the acetyl-
ation dictated microtubule stability or whether stabilized
microtubules became more extensively modified [25].
Nevertheless, tubulin acetylation helps in stability by
promoting salt bridge formation between adjacent proto-
filaments [26]. In the presence of tau protein, acetylated
tubulin makes microtubule resistant to the action of sev-
ering protein katanin [27]. Functional studies demon-
strated that acetylation of α-tubulin is essential for the
association of motor proteins (i.e., dynein and kinesin)
with microtubules and enhances kinesin-based transport
in cells [28–30]. However, these observations were not
confirmed in purified cell free system [31, 32], suggest-
ing that tubulin acetylation may indirectly impact intra-
cellular transport requiring additional factors in cells.
We suspect that the increased proportion of acetylated
tubulin in AD may represent an adaptive change in
compensation for the loss of microtubules and their as-
sociated deficits in axonal transport along microtubules.
Such a notion is supported by the finding that acetylated
tubulin can be stress-induced in the hippocampus [33]
and tubulin hyperacetylation appears to be a common
response to several cellular stresses by modulating the
binding and function of signaling factors essential for
cell survival [34–36]. In this regard, it is of interest tonote that inhibition of histone deacetylase 6 (HDAC6),
the major tubulin deacetylase, increased the amount of
acetylated tubulin and concomitantly stimulated vesicu-
lar transport of brain-derived neurotrophic factor in
neuronal cell lines and compensates for the transport
deficit in Huntington’s disease models [37]. Similarly, a
recent study found HDAC6 null mutation rescued tau-
induced microtubule defects in drosophila through
increased tubulin acetylation [38]. In fact, HDAC6 inhib-
ition alleviates cognitive deficits in transgenic mouse
models of AD [39, 40] and also improves memory in a
mouse model of tau deposits [41].
Another interesting finding of this study is the better
preserved number of processes decorated by polygluta-
mylated tubulin recognized by the B3 polyglutamylated
tubulin antibody which demonstrated significantly in-
creased ratio in the remaining processes positive for
α-tubulin. Tubulin polyglutamylation is abundant in neu-
rons which involves the addition of one to six glutamyl
units to γ-carboxyl group of glutamate at the C-terminal
tail domain of both α- and β-tubulin [42–44]. Because we
focused on modifications to α-tubulin, we chose to use
the B3 monoclonal polyglutamylation antibody which
preferentially recognizes polyglutamylated α-tubulin [45].
However, since this antibody recognizes only polyglutamy-
lated α-tubulin containing side chains with ≥2 glutamate
residues [45, 46], it must be emphasized that it does not
provide information of all forms glutamylated α-tubulin
due to the obvious lack of detection for monoglutamylated
form. The function of tubulin polyglutamylation remains
poorly characterized partly due to the complex tubulin
polyglutamylation patterns [47], but it is believed that
tubulin glutamylation is involved in fine-tuning a range
of microtubule functions by regulating the binding to
microtubule of various microtubule-associated proteins
including tau, MAP1A, 1B and 2 and motor proteins in-
cluding both kinesins and dyneins [48–51]. For example,
kinesin-1 motility is increased by tubulin polyglutamyla-
tion [52] and in vivo study suggested polyglutamylation of
α-tubulin as a molecular traffic sign for correct targeting
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mission [51]. Therefore, such an increased ratio of poly-
glutamylated tubulin in the remaining tubulin-positive
processes may help to preserve essential functions of mi-
crotubules such as axonal transport. The recent finding of
tubulin polyglutamylation stimulated spastin-mediated
microtubule severing suggest that tubulin polyglutamyla-
tion could act as a signal to control microtubule mass and
stability within a cell [53]. However such a signal is likely
context specific and the outcomes are mediated by
spatially restricted tubulin interactors of diverse nature
within the same cell since another study demonstrated
that hyperelongation of glutamyl side chains stabilized
cytoplasmic microtubules and destabilized axonemal mi-
crotubules [54]. It is possible that the increased polygluta-
mylated tubulin in the soma along with its reduction in
the neuronal process observed in human AD brain may
represent an adaptation process helping to stabilize the
microtubule structures so as to compensate for the overall
loss of microtubules.
Comparing the length of tubulin-positive axons in neu-
rons with or without NFTs in AD and control brain re-
vealed that NFT-free neurons demonstrated similar length
between AD and control, suggesting there is no specific
effects of disease state. We found that NFT formation
caused reduced length of axonal processes decorated by
α-tubulin and its modified forms in NFT-bearing neurons
in both AD and control patients, indicating a specific det-
rimental and cell autonomous effect of tau pathology on
microtubule. This is likely a gradual and chronic process
because significant numbers of NFT-bearing neurons still
display long axons similar to that of NFT-free neurons.
Prior studies demonstrated a selective loss of acetylated
tubulin in the NFT-bearing neurons [14]. We did not
find such a pattern. Many NFT-bearing neurons with
long axons demonstrated similar levels of acetylated
tubulin comparable to neighboring NFT-free neurons,
while in those NFT-bearing neurons without long
axons, acetylated tubulin was detected in the cell body.
Similar observations were made for polyglutamylated
tubulin as well. These data suggest that the detrimental
effects of tau pathology on microtubule are unlikely me-
diated through the selective reduction of specific post-
translational modifications of tubulin.
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